Patents by Inventor Tohru Kambe

Tohru Kambe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230190698
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: February 15, 2023
    Publication date: June 22, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Patent number: 11617733
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: April 4, 2023
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru Kambe, Toru Maruyama, Shinsaku Yamane, Satoshi Nakayama, Kousuke Tani
  • Publication number: 20220089532
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji NOJIMA, Kenji SASAKI, Tohru KAMBE, Takashi KONEMURA, Yoshikazu GOTO
  • Patent number: 11261154
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: March 1, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji Nojima, Kenji Sasaki, Tohru Kambe, Takashi Konemura, Yoshikazu Goto
  • Publication number: 20210332009
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Application
    Filed: July 30, 2019
    Publication date: October 28, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji NOJIMA, Kenji SASAKI, Tohru KAMBE, Takashi KONEMURA, Yoshikazu GOTO
  • Publication number: 20210169842
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: January 14, 2021
    Publication date: June 10, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Patent number: 10940134
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: March 9, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru Kambe, Toru Maruyama, Shinsaku Yamane, Satoshi Nakayama, Kousuke Tani
  • Patent number: 10899729
    Abstract: A method for producing a compound, such as 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate, and a novel intermediate suitable for the method, whereby the compound can be stably supplied with a high total reaction yield, by changing the starting material and improving the metathesis reaction, asymmetric reduction reaction and the like.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 26, 2021
    Assignee: ONO PHARMACEUTICAL CO.. LTD.
    Inventors: Hideki Moriguchi, Yusuke Tanaka, Tatsunori Ino, Tohru Kambe, Taihei Nishiyama, Shinichiro Tsujiyama, Yohei Ueda
  • Publication number: 20200093781
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 26, 2020
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Publication number: 20190315705
    Abstract: A method for producing a compound, such as 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate, and a novel intermediate suitable for the method, whereby the compound can be stably supplied with a high total reaction yield, by changing the starting material and improving the metathesis reaction, asymmetric reduction reaction and the like.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 17, 2019
    Applicant: ONO PHARMACEUTICALS CO., LTD.
    Inventors: Hideki MORIGUCHI, Yusuke TANAKA, Tatsunori INO, Tohru KAMBE, Taihei NISHIYAMA, Shinichiro TSUJIYAMA, Yohei UEDA
  • Publication number: 20190111019
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Patent number: 10201520
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: February 12, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru Kambe, Toru Maruyama, Shinsaku Yamane, Satoshi Nakayama, Kousuke Tani
  • Publication number: 20180116995
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Patent number: 9889114
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: February 13, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru Kambe, Toru Maruyama, Shinsaku Yamane, Satoshi Nakayama, Kousuke Tani
  • Publication number: 20160287551
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: June 13, 2016
    Publication date: October 6, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Patent number: 9388157
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: July 12, 2016
    Assignee: ONO PHARMACEUTICALS CO., LTD.
    Inventors: Tohru Kambe, Toru Maruyama, Shinsaku Yamane, Satoshi Nakayama, Kousuke Tani
  • Patent number: 9150537
    Abstract: Provided is a compound which has strong intraocular pressure lowering action and has no side effect on eyes such as ocular stimulating property, humor protein rise etc. Since a compound represented by the formula (I): (wherein definition of each group is as described in the specification), or a salt thereof, a solvate thereof, or a prodrug thereof has strong intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: October 6, 2015
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toru Maruyama, Tohru Kambe, Shinsaku Yamane, Satoshi Nakayama
  • Patent number: 9029574
    Abstract: Provided is a compound which has strong and sustaining intraocular pressure lowering action and, further, has no fear of side effect on eyes. Since a compound represented by the formula (I): wherein definition of each group is as described in the specification, or a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering action and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: May 12, 2015
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Tohru Kambe, Isamu Sugimoto
  • Publication number: 20150112079
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 23, 2015
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Patent number: 8962868
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: February 24, 2015
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Tohru Kambe, Toru Maruyama, Shinsaku Yamane, Satoshi Nakayama, Kousuke Tani